These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26083953)

  • 1. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial.
    Kong Y; Zhang W; Jiang Z; Wang L; Li C; Li Y; Xia J
    Hum Vaccin Immunother; 2015; 11(10):2425-33. PubMed ID: 26083953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly.
    Huang L; Wang L; Li H; Hu Y; Ru W; Han W; Shi G; Ye Q; Han Z; Xia J; Xia S; Xu M; Li J
    Hum Vaccin Immunother; 2019; 15(1):249-255. PubMed ID: 30215583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.
    Thisyakorn U; Chokephaibulkit K; Kosalaraksa P; Benjaponpitak S; Pancharoen C; Chuenkitmongkol S
    Hum Vaccin Immunother; 2014; 10(7):1859-65. PubMed ID: 25424793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.
    Bryant KA; Frenck R; Gurtman A; Rubino J; Treanor J; Thompson A; Jones TR; Sundaraiyer V; Baxter LM; Gruber WC; Emini EA; Scott DA; Schmoele-Thoma B
    Vaccine; 2015 Oct; 33(43):5854-5860. PubMed ID: 26362099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 2 to 70 year old healthy people in China: A phase III double blind, randomized clinical trial.
    Li G; Liang Q; Shi J; Hu Y; Li H; Wei W; Zhu F; Ye Q
    Hum Vaccin Immunother; 2015; 11(3):699-703. PubMed ID: 25714798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.
    Ciprero K; Zykov KA; Briko NI; Shekar T; Sterling TM; Bitieva E; Stek JE; Musey L
    Hum Vaccin Immunother; 2016 Aug; 12(8):2142-2147. PubMed ID: 27149114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.
    Shiramoto M; Hanada R; Juergens C; Shoji Y; Yoshida M; Ballan B; Cooper D; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2015; 11(9):2198-206. PubMed ID: 26176163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
    Severance R; Schwartz H; Dagan R; Connor L; Li J; Pedley A; Hartzel J; Sterling TM; Nolan KM; Tamms GM; Musey LK; Buchwald UK
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 34726574
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial.
    Clarke E; Bashorun AO; Okoye M; Umesi A; Badjie Hydara M; Adigweme I; Dhere R; Sethna V; Kampmann B; Goldblatt D; Tate A; Weiner DH; Flores J; Alderson MR; Lamola S
    Vaccine; 2020 Jan; 38(2):399-410. PubMed ID: 31843266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
    Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
    Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
    Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
    Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
    Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
    Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W
    Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.
    Hamaluba M; Kandasamy R; Upreti SR; Subedi GR; Shrestha S; Bhattarai S; Gurung M; Pradhan R; Voysey M; Gurung S; Pradhan S; Thapa AK; Maharjan R; Kiran U; Kerridge SA; Hinds J; van der Klis F; Snape MD; Murdoch DR; Kelly S; Kelly DF; Adhikari N; Thorson S; Pollard AJ
    Lancet Infect Dis; 2015 Apr; 15(4):405-14. PubMed ID: 25701560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.